GCIScancell gains on appointment of Dr Florian Reinaud to Board
() , a developer of immunotherapies for the treatment of cancer, announced that Dr Florian Reinaud of Redmile Group has been appointed as a Non-Executive Director to Scancell's Board of Directors.
Reinaud is a life sciences professional with 20 years of experience across established pharmaceutical companies, startups, and healthcare investment organisations. He is currently on the investment team at Redmile, a healthcare sector-focused investment firm.
Reinaud began his career as a medical doctor in the NHS before moving to Schroders Salomon Smith Barney - Citigroup's European investment banking arm - where he worked as an equity analyst covering pan-European medtech and healthcare services. He then transitioned to the healthcare team at Apax Partners in Paris, advising on and executing venture and late-stage investments.
After his time at Apax, Reinaud became the first CFO of Paris-based DBV Technologies, a biopharma specialising in allergy diagnosis and treatment. He then went on to serve as partner at CDC Innovation Capital, a French venture capital firm focused on investments in healthcare services, for 6 years. Reinaud later co-founded and served as CEO of Concilio, a medical concierge service, for 6 years, before joining Redmile.
Jean-Michel Cosséry, Non-Executive Chairman of Scancell, commenting on the appointment:
"On behalf of the Board, I am pleased to welcome Florian to Scancell, where he will represent one of the Company's key investors. His broad biopharmaceutical industry and financial experience, coupled with his strong relationships with the investment community and first-hand experience in the medical field, will be invaluable as we continue to advance our lead assets through later stage clinical development, and I am confident he will add significant value to the Company."
shares jumped 7.7% on the announcement.
Follow News & Updates from Scancell:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.